Divalproex Sodium Tablet, Delayed Release
Product Images NDC 57237-048

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 57237-048). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Divalproex Fig1)

Figure 1 (Divalproex Fig1)
This appears to be a figure from a study, showing the results of two different studies (Study 1 and Study 2). The abbreviations PBO, DVPK, P80, and DVPX are used, which may refer to different treatments or measurements used in the studies. There is a note that indicates that *p<0.05, which suggests that some statistical analysis has been done and there may be a significant difference between the groups shown in the figure.*
FDA Label Image

Figure 2 (Divalproex Fig2)

Figure 2 (Divalproex Fig2)
FDA Label Image

Figure 3 (Divalproex Fig3)

Figure 3 (Divalproex Fig3)
The text provides a graph showing the percentage reduction in CPS rate based on the dosage of a certain medication. The graph has two curves: High dose and low dose. The X-axis shows the percentage of patients, while the Y-axis indicates the level of improvement, no change, or worsening. However, there is no further information available to provide additional context.*
FDA Label Image

Figure 4 (Divalproex Fig4)

Figure 4 (Divalproex Fig4)
The text describes the mean 4-week migraine rates for Placebo and Divalproex Sodium in two different studies. The dose of Divalproex Sodium delayed-release tablets ranged from 500 to 1087 mg/day.*
FDA Label Image

Package Label-principal Display Panel (125 mg (100 Tablets Bottle))

Package Label-principal Display Panel (125 mg (100 Tablets Bottle))
This text describes the drug "Divalproex sodium USP" and its usual dosage as a delayed-release tablet. It also includes instructions for pharmacists to dispense the medication in a tightly sealed, light-resistant container and to check that the seal over the bottle is not broken or missing. The drug should be stored within the temperature range of 20 to 25°C (68° to 77°F), with excursions permitted to 15° to 30°C (59° to 86°F). The text also provides a code and revision date for the full prescribing information.*
FDA Label Image

Package Label-principal Display Panel (250 mg (100 Tablets Bottle))

Package Label-principal Display Panel (250 mg (100 Tablets Bottle))
Each enteric-coated delayed-release tablet of Rising® (NDC 57237-047-01) contains 5 Divalproex Sodium USP equivalent to Valproic Acid 250 mg. Rising Health, LLC distributes Rising® from Saddle Brook, NJ 07663. Rising® is made in India and the usual dosage is dependent on prescribed guidelines enclosed in the full prescribing information with tablets, USP. Store Rising® between 20°C to 25°C (68°F to 77°F) and permit excursions between 15°C to 30°C (59°F to 86°F) to ensure maintained Valproic Acid activity. Rising® is to be dispensed by a pharmacist, who must verify a seal over the bottle and store it in a USP tight, light-resistant container. Rising® is available in 100 tablet bottles and the specification printing is permitted in a designated zone.*
FDA Label Image

Package Label-principal Display Panel (500 mg (100 Tablets Bottle))

Package Label-principal Display Panel (500 mg (100 Tablets Bottle))
FDA Label Image

Chemical Structure (Divalproex Str)

Chemical Structure (Divalproex Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.